Search
ALX Oncology Holdings Inc
ALXOAdd to Watchlist
1.340USD
-0.030-2.19%
Market hours 11/03, 09:40（ET）
167.39MMarket Cap
LossP/E TTM
ALX Oncology Holdings Inc (ALXO) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to ALX Oncology Holdings Inc in the past month.
Buy
1 Strong Buy
5 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
4.600USD+289.83%
ALXO Analyst Recommendation Trends
In the current month, ALXO has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ALXO average Analyst price target in the last month is 4.600.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
1
1
1
1
1
1
5
5
5
5
5
5
5
5
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
7
7
7
7
7
ALXO Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Financial Forecasting
Based on analysts' estimates, ALXO EPS is projected to reach -0.138 in FY2026Q3, following reported EPS of -0.132 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.36
-0.19
-0.14
-0.14
-0.14
Actual
-0.42
-0.17
-0.13
--
--
Surprise
-16.12%
+11.63%
+7.56%
--
--
FAQs
What is ALX Oncology Holdings Inc's price target?
Analysts forecast that ALX Oncology Holdings Inc's price target is USD 4.60, with the highest forecast at USD 6.00 and the lowest forecast at USD 4.00.
How have ALX Oncology Holdings IncALXO's recent earnings per share performed?
The market expectation was USD -0.13, while ALX Oncology Holdings IncALXO's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for ALX Oncology Holdings Inc?
Based on the ratings of ALX Oncology Holdings Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.